Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DSM Biologics to manufacture Morphosys antibody

This article was originally published in Scrip

Executive Summary

DSM Biologics is to manufacture Morphosys's fully human HuCAL antibody MOR202, a promising target for the treatment of multiple myeloma. The two firms have signed a biopharmaceutical manufacturing agreement covering process development and cGMP manufacturing of MOR202, though no financial details were disclosed. DSM Biologics will manufacture the compound in its cGMP facilities in Groningen, the Netherlands. DSM Biologics also manufactures Morphosys's MOR103, which targets inflammation. Morphosys will continue to use Crucell's PER C6 technology platform for the large-scale manufacture of biopharmaceuticals.

Topics

Related Companies

UsernamePublicRestriction

Register

SC002550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel